Cleveland BioLabs, Inc (CBLI)

Oncology Corporate Profile

Stock Performance

2.3600
0.0500

HQ Location

73 High Street
Buffalo, NY 14203

Company Description

Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. CBL0137 is under development by Incuron, LLC, a joint venture based in the Russian Federation that was founded in 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and Cleveland BioLabs. Cleveland BioLabs, Inc. conducts business in the United States and in the Russian Federation through its wholly and majority owned operating subsidiaries. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia for Medical Research.

Website: http://www.cbiolabs.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
entolimodtoll-like receptor 5 (TLR5)Colorectal cancerI
mobilanoncolytic virusProstate cancerI
entolimodtoll-like receptor 5 (TLR5)Various cancer typesI

View additional information on product candidates here »

Source: http://www.cbiolabs.com

Recent News Headlines

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/22/2017 12:17 pm

5/15/2017 06:17 am

5/15/2017 06:17 am

5/15/2017 06:17 am

5/15/2017 06:17 am

4/20/2017 06:17 am

4/20/2017 06:17 am

4/20/2017 06:17 am

4/20/2017 06:17 am

4/19/2017 12:17 pm

4/18/2017 06:17 am

4/18/2017 06:17 am

4/18/2017 06:17 am

4/11/2017 12:17 pm

4/7/2017 12:17 pm

Cleveland BioLabs Reports 2016 Financial Results and Development Progress

2/22/2017 09:01 pm

[Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the fourth quarter and year ended December 31, 2016.